Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 188

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 188
---
727)   ​   ​          (85,027)   ​   ​     7%
TYK2 program on GLPG3667            ​   ​     (34,965)   ​    ​     (31,289)   ​    ​     (24,467)   ​   ​          (90,721)   ​   ​     7%
Cell therapy programs in oncology   ​   ​    (170,998)   ​    ​     (82,218)   ​    ​     (29,999)   ​   ​         (283,215)   ​   ​    22%
Other discovery programs            ​   ​    (111,096)   ​    ​    (108,887)   ​    ​    (166,507)   ​   ​         (386,490)   ​   ​    30%
Total R&amp;D expenses              ​   €    (343,611)   ​    €    (431,471)   ​    €    (515,083)   ​   €       (1,290,165)   ​   ​   100%
​
Other programs comprise expenditure for other projects in research phase and other early stage development programs in inflammation, fibrosis and other indications.
The decrease in our total R&D expenditure (before discontinued operations) for the year ended December 31, 2024, compared to the year before, was primarily due to reduced spend on the filgotinib development. This was partly offset by cost increases for our cell therapy programs in oncology, our TYK2 program in immunology and our other discovery programs. 
The decrease in our R&D expenditure for the filgotinib development is explained by the discontinuation of the DIVERSITY clinical trial in CD in 2023 and the transfer of the Jyseleca® business to Alfasigma in 2024.
Sales and marketing expenses
Sales and marketing expenses primarily include costs associated with managing the commercial activities related to Jyseleca® in Europe, as well as expenses related to investments in strategic marketing in oncology.

​
136

Expenses on S&M activities are recognized as an expense in the period in which the expense is incurred.
Our sales and marketing expenses consists of costs associated with our commercial activities such as:

●   personnel costs associated with employing our team of commercial and supply chain staff, including salaries, social security costs, and share-based compensation expenses;
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------